Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 17/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.59 |
| ▸ | AOC2 | O75106 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16067614 | 0.96 | AOC3 (0.78) | AOC3KCNH2AOC2 | |
| Hydrochloric Acid SCHEMBL16048707 | 0.95 | AOC3 (0.77) | AOC3KCNH2AOC2 | |
| SCHEMBL25765239 | 0.87 | AOC3 (0.78) | AOC3KCNH2 | |
| SCHEMBL16048406 | 0.86 | KCNH2 (0.78) | AOC3KCNH2 | |
| SCHEMBL30026179 | 0.86 | KCNH2 (0.78) | AOC3KCNH2 | |
| SCHEMBL17611248 | 0.84 | AOC3 (0.78) | AOC3KCNH2 | |
| SCHEMBL16047562 | 0.84 | AOC3 (1.00) | AOC3KCNH2 | |
| SCHEMBL30026916 | 0.84 | AOC3 (1.00) | AOC3KCNH2 | |
| SCHEMBL23870667 | 0.82 | AOC3 (0.74) | AOC3KCNH2 | |
| SCHEMBL22819192 | 0.82 | AOC3 (0.82) | AOC3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190728-A1 | NEW THERAPEUTIC USES OF COMPOUNDS | PROXIMAGEN LLC (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230190728-A1 | NEW THERAPEUTIC USES OF COMPOUNDS | PROXIMAGEN LLC (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230190728-A1 | NEW THERAPEUTIC USES OF COMPOUNDS | PROXIMAGEN LLC (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230110165-A1 | Substituted Imidazo[4,5-c]pyridine Compounds and Compositions Thereof | PROXIMAGEN LLC (US) | 2023-04-13 | — | — | US | disclosed |
| US-11512082-B2 | Substituted imidazo[4,5-c]pyridine compounds and compositions thereof | PROXIMAGEN, LLC (US) | 2022-11-29 | — | — | US | disclosed |
| WO-2021195406-A1 | NEW THERAPEUTIC USES OF COMPOUNDS | PROXIMAGEN, LLC (US) | 2021-09-30 | — | — | WO | disclosed |
| US-10968223-B2 | Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors | PROXIMAGEN, LLC (US) | 2021-04-06 | — | — | US | disclosed |
| US-10968223-B2 | Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors | PROXIMAGEN, LLC (US) | 2021-04-06 | — | — | US | disclosed |
| US-20200347059-A1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | PROXIMAGEN, LLC (US) | 2020-11-05 | — | — | US | disclosed |
| US-20200347059-A1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | PROXIMAGEN, LLC (US) | 2020-11-05 | — | — | US | disclosed |
| US-20160046622-A1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | PROXIMAGEN, LLC | 2016-02-18 | — | — | US | disclosed |
| EP-2970260-A1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | Proximagen Limited (GB) | 2016-01-20 | — | — | EP | disclosed |
| US-20150258101-A1 | NEW COMPOUNDS | PROXIMAGEN LIMITED (GB) | 2015-09-17 | — | — | US | disclosed |
| US-20150258101-A1 | NEW COMPOUNDS | PROXIMAGEN LIMITED (GB) | 2015-09-17 | — | — | US | disclosed |
| US-20150258101-A1 | NEW COMPOUNDS | PROXIMAGEN LIMITED (GB) | 2015-09-17 | — | — | US | disclosed |
| WO-2014140592-A1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | PROXIMAGEN LIMITED (GB) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014140592-A1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | PROXIMAGEN LIMITED (GB) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275040-A1 | NEW COMPOUNDS | PROXIMAGEN LIMITED (GB) | 2014-09-18 | — | — | US | disclosed |
| US-20140275040-A1 | NEW COMPOUNDS | PROXIMAGEN LIMITED (GB) | 2014-09-18 | — | — | US | disclosed |
| US-20140275040-A1 | NEW COMPOUNDS | PROXIMAGEN LIMITED (GB) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11512082-B2 | Substituted imidazo[4,5-c]pyridine compounds and compositions thereof | PNPO, XDH, EPX | AOC3 12/4885KCNH2 315/4885AOC2 14/4885 |
| US-20140275040-A1 | NEW COMPOUNDS | SSB, ALOX15B, ALOX12 | AOC3 133/4885KCNH2 4546/4885AOC2 85/4885 |
| US-20230190728-A1 | NEW THERAPEUTIC USES OF COMPOUNDS | ACE2, TMPRSS2, IL1B | AOC3 2604/4885KCNH2 800/4885AOC2 3567/4885 |
| US-10968223-B2 | Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors | PNPO, PPOX, SCO2 | AOC3 7/4885KCNH2 448/4885AOC2 4/4885 |
| US-20230110165-A1 | Substituted Imidazo[4,5-c]pyridine Compounds and Compositions Thereof | PNPO, XDH, EPX | AOC3 12/4885KCNH2 315/4885AOC2 14/4885 |
| US-20200347059-A1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | PNPO, PPOX, SCO2 | AOC3 7/4885KCNH2 448/4885AOC2 4/4885 |
| US-20160046622-A1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | PNPO, AOC3, IL4I1 | AOC3 2/4885KCNH2 570/4885AOC2 4/4885 |
| US-20150258101-A1 | NEW COMPOUNDS | AOX1, QSOX1, MAOB | AOC3 85/4885KCNH2 2492/4885AOC2 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.